Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APOMYGRE: MMF Dose Optimization in Kidney Transplant
NCT00199667Phase 4Unknown
- Sponsor
- CHU de Limoges
- Start
- Oct 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of mycophenolate mofetil in kidney transplant rejection (2 arms), sponsored by CHU de Limoges. Primary endpoint: Immunosuppressant Treatment Failure at 12 months. Status: unknown.
02
Drugs
mycophenolate mofetil
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00199667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00199667.